These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 32665104)
1. A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies. Demmon S; Bhargava S; Ciolek D; Halley J; Jaya N; Joubert MK; Koepf E; Smith P; Trexler-Schmidt M; Tsai P Biologicals; 2020 Sep; 67():9-20. PubMed ID: 32665104 [TBL] [Abstract][Full Text] [Related]
2. Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm. Van Buskirk GA; Asotra S; Balducci C; Basu P; DiDonato G; Dorantes A; Eickhoff WM; Ghosh T; González MA; Henry T; Howard M; Kamm J; Laurenz S; MacKenzie R; Mannion R; Noonan PK; Ocheltree T; Pai U; Poska RP; Putnam ML; Raghavan RR; Ruegger C; Sánchez E; Shah VP; Shao ZJ; Somma R; Tammara V; Thombre AG; Thompson B; Timko RJ; Upadrashta S; Vaithiyalingam S; AAPS PharmSciTech; 2014 Jun; 15(3):665-93. PubMed ID: 24578237 [TBL] [Abstract][Full Text] [Related]
3. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies. Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375 [TBL] [Abstract][Full Text] [Related]
4. An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations. Halley J; Chou YR; Cicchino C; Huang M; Sharma V; Tan NC; Thakkar S; Zhou LL; Al-Azzam W; Cornen S; Gauden M; Gu Z; Kar S; Lazar AC; Mehndiratta P; Smith J; Sosic Z; Weisbach P; Stokes ESE J Pharm Sci; 2020 Jan; 109(1):6-21. PubMed ID: 31563512 [TBL] [Abstract][Full Text] [Related]
5. Use of benchmarking in the development of biopharmaceutical products. Giffin M; McLeish S Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932 [TBL] [Abstract][Full Text] [Related]
6. Toward biotherapeutic product real-time quality monitoring. Guerra A; von Stosch M; Glassey J Crit Rev Biotechnol; 2019 May; 39(3):289-305. PubMed ID: 30724608 [TBL] [Abstract][Full Text] [Related]
8. [The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs]. Saitoh S Yakugaku Zasshi; 2018; 138(12):1475-1481. PubMed ID: 30504661 [TBL] [Abstract][Full Text] [Related]
9. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650 [TBL] [Abstract][Full Text] [Related]
10. Scientific, statistical, practical, and regulatory considerations in design space development. Debevec V; Srčič S; Horvat M Drug Dev Ind Pharm; 2018 Mar; 44(3):349-364. PubMed ID: 29200316 [TBL] [Abstract][Full Text] [Related]
11. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets. Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852 [TBL] [Abstract][Full Text] [Related]
12. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. Farid SS; Baron M; Stamatis C; Nie W; Coffman J MAbs; 2020; 12(1):1754999. PubMed ID: 32449439 [TBL] [Abstract][Full Text] [Related]
13. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. Grangeia HB; Silva C; Simões SP; Reis MS Eur J Pharm Biopharm; 2020 Feb; 147():19-37. PubMed ID: 31862299 [TBL] [Abstract][Full Text] [Related]
15. Roadmap for implementation of quality by design (QbD) for biotechnology products. Rathore AS Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883 [TBL] [Abstract][Full Text] [Related]
16. A design space exploration for control of Critical Quality Attributes of mAb. Bhatia H; Read E; Agarabi C; Brorson K; Lute S; Yoon S Int J Pharm; 2016 Oct; 512(1):242-252. PubMed ID: 27575657 [TBL] [Abstract][Full Text] [Related]
17. A quality by design study applied to an industrial pharmaceutical fluid bed granulation. Lourenço V; Lochmann D; Reich G; Menezes JC; Herdling T; Schewitz J Eur J Pharm Biopharm; 2012 Jun; 81(2):438-47. PubMed ID: 22446063 [TBL] [Abstract][Full Text] [Related]
18. Strategies for Maximizing Successful Drug Substance Technology Transfer Using Engineering, Shake-Down, and Wet Test Runs. Abraham S; Bain D; Bowers J; Larivee V; Leira F; Xie J PDA J Pharm Sci Technol; 2015; 69(5):650-7. PubMed ID: 26429113 [TBL] [Abstract][Full Text] [Related]